Article
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
International journal of chronic obstructive pulmonary disease - 1 Jan 2012
Schmid S T, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas D A, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla A R
Abstract excerpt
BACKGROUND: The major concept behind augmentation therapy with human α(1)-antitrypsin (AAT) is to raise the levels of AAT in patients with protease inhibitor phenotype ZZ (Glu342Lys)-inherited AAT deficiency and to protect lung tissues from proteolysis and progression of emphysema. OBJECTIVE: To evaluate the short-term effects of augmentation therapy (Prolastin) on plasma levels of AAT, C-reactive protein, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.